| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection MW Fried, ML Shiffman, KR Reddy, C Smith, G Marinos, FL Gonçales Jr, ... New England journal of medicine 347 (13), 975-982, 2002 | 8633 | 2002 |
| Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose SJ Hadziyannis, H Sette Jr, TR Morgan, V Balan, M Diago, P Marcellin, ... Annals of internal medicine 140 (5), 346-355, 2004 | 3981 | 2004 |
| Telaprevir for retreatment of HCV infection S Zeuzem, P Andreone, S Pol, E Lawitz, M Diago, S Roberts, R Focaccia, ... New England Journal of Medicine 364 (25), 2417-2428, 2011 | 2115 | 2011 |
| Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis E Vilar-Gomez, Y Martinez-Perez, L Calzadilla-Bertot, A Torres-Gonzalez, ... Gastroenterology 149 (2), 367-378. e5, 2015 | 2111 | 2015 |
| Peginterferon alfa-2a in patients with chronic hepatitis C S Zeuzem, SV Feinman, J Rasenack, EJ Heathcote, MY Lai, E Gane, ... New England Journal of Medicine 343 (23), 1666-1672, 2000 | 1721 | 2000 |
| Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B P Marcellin, GKK Lau, F Bonino, P Farci, S Hadziyannis, R Jin, ZM Lu, ... New England Journal of Medicine 351 (12), 1206-1217, 2004 | 1521 | 2004 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1044 | 2019 |
| Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients M Romero-Gómez, MDM Viloria, RJ Andrade, J Salmerón, M Diago, ... Gastroenterology 128 (3), 636-641, 2005 | 926 | 2005 |
| Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin P Ferenci, MW Fried, ML Shiffman, CI Smith, G Marinos, FL Gonçales Jr, ... Journal of hepatology 43 (3), 425-433, 2005 | 673 | 2005 |
| A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin MG Swain, MY Lai, ML Shiffman, WGE Cooksley, S Zeuzem, DT Dieterich, ... Gastroenterology 139 (5), 1593-1601, 2010 | 514 | 2010 |
| Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment JM Sánchez–Tapias, M Diago, P Escartín, J Enríquez, M Romero–Gómez, ... Gastroenterology 131 (2), 451-460, 2006 | 472 | 2006 |
| Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels S Zeuzem, M Diago, E Gane, KR Reddy, P Pockros, D Prati, M Shiffman, ... Gastroenterology 127 (6), 1724-1732, 2004 | 358 | 2004 |
| Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy T Poynard, M Colombo, J Bruix, E Schiff, R Terg, S Flamm, ... Gastroenterology 136 (5), 1618-1628. e2, 2009 | 336 | 2009 |
| Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B F Bonino, P Marcellin, GKK Lau, S Hadziyannis, R Jin, T Piratvisuth, ... Gut 56 (5), 699-705, 2007 | 319 | 2007 |
| Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C M Romero-Gómez, CM Fernández-Rodríguez, RJ Andrade, M Diago, ... Journal of hepatology 48 (5), 721-727, 2008 | 228 | 2008 |
| Peginterferon alfa-2a (40 kD)(PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining … SJ Hadziyannis, H Cheinquer, T Morgan, M Diago, DM Jensen, H Sette, ... Elsevier Science Bv, 2002 | 222 | 2002 |
| Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected … M Diago, G Castellano, J Garcia-Samaniego, C Perez, I Fernandez, ... Gut 55 (3), 374-379, 2006 | 198 | 2006 |
| Pegylated (40kDa) interferon alfa-2a (PEGASYS®) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study MW Fried, ML Shiffman, RK Reddy, C Smith, G Marino, F Goncales, ... Gastroenterology 5 (120), A55, 2001 | 194 | 2001 |
| Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort JL Calleja, J Crespo, D Rincón, B Ruiz-Antorán, I Fernandez, C Perelló, ... Journal of hepatology 66 (6), 1138-1148, 2017 | 189 | 2017 |
| Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa‐2a plus ribavirin M Romero‐Gómez, M Diago, RJ Andrade, JL Calleja, J Salmerón, ... Hepatology 50 (6), 1702-1708, 2009 | 186 | 2009 |
